Freenome raises $254 million in new funding to accelerate its platform for early cancer detection

– roche led the financing alongside existing and new investors – – the funds will progress clinical programs and expand platform capabilities – south san francisco, calif. , feb. 15, 2024 /prnewswire/ -- freenome, a biotechnology company developing blood tests for early cancer detection, announced the addition of $254 million from new and existing investors.

DGX Ratings Summary

DGX Quant Ranking